[CAS NO. 1238697-26-1] TAK-063
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:
PRODUCTS SPECIFICATIONS [1238697-26-1]
Store
Catalog
SLK-S8459
Brand
Selleck
CAS
1238697-26-1
DESCRIPTION [1238697-26-1]
Overview
| MDL | MFCD28385852 |
|---|---|
| Molecular Weight | 428.42 |
| Molecular Formula | C23H17FN6O2 |
| SMILES | FC1=CC(N2N=CC=C2)=CC=C1N3N=C(C4=CC=NN4C5=CC=CC=C5)C(C(OC)=C3)=O |
For research use only.
Storage
3 years,-20°C,powder
1 years,-80°C,in solvent
1 years,-80°C,in solvent
Shipping
Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)
Preparing Stock Solutions
| 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3342 mL | 11.6708 mL | 23.3416 mL |
| 5 mM | 0.4668 mL | 2.3342 mL | 4.6683 mL |
| 10 mM | 0.2334 mL | 1.1671 mL | 2.3342 mL |
| 50 mM | 0.0467 mL | 0.2334 mL | 0.4668 mL |
Description
TAK-063 (Balipodect) is a novel and selective inhibitor with an IC50 of 0.30 nM.
Targets
| PDE10A [1] (Cell-free assay) |
| 0.3 nM |
In vivo
TAK-063 has high brain penetration in mice. Oral administration of TAK-063 to mice elevated striatal cAMP and (cGMP) levels at 0.3 mg/kg and shows potent suppression of phencyclidine (PCP)-induced hyperlocomotion at a minimum effective dose (MED) of 0.3 mg/kg. TAK-063 is currently being evaluated in clinical trials for the treatment of schizophrenia.
Powered by Arctom Copyright © 2026 Arctom. All rights
reserved.